Details for New Drug Application (NDA): 071426
✉ Email this page to a colleague
NDA 071426 describes VINCASAR PFS, which is a drug marketed by Teva Parenteral and is included in one NDA. Additional details are available on the VINCASAR PFS profile page.
The generic ingredient in VINCASAR PFS is vincristine sulfate. There are thirteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the vincristine sulfate profile page.
The generic ingredient in VINCASAR PFS is vincristine sulfate. There are thirteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the vincristine sulfate profile page.
Summary for 071426
| Tradename: | VINCASAR PFS |
| Applicant: | Teva Parenteral |
| Ingredient: | vincristine sulfate |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 071426
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | 1MG/ML | ||||
| Approval Date: | Jul 17, 1987 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
